{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T07:58:18Z","timestamp":1792828698570,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T00:00:00Z","timestamp":1325808000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1007\/s00259-011-2031-6","type":"journal-article","created":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T04:46:53Z","timestamp":1325825213000},"page":"569-580","source":"Crossref","is-referenced-by-count":145,"title":["Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET\/CT in patients with recurrent medullary thyroid carcinoma"],"prefix":"10.1007","volume":"39","author":[{"given":"Giorgio","family":"Treglia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Castaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Felicia","family":"Villani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germano","family":"Perotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"de Waure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelina","family":"Filice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Ambrosini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Cremonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Santimaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annibale","family":"Versari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Fanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittoria","family":"Rufini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,1,6]]},"reference":[{"key":"2031_CR1","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.clon.2010.05.002","volume":"22","author":"F Pacini","year":"2010","unstructured":"Pacini F, Castagna MG, Cipri C, Schlumberger M. Medullary thyroid carcinoma. Clin Oncol. 2010;22:475\u201385.","journal-title":"Clin Oncol"},{"key":"2031_CR2","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1139::AID-CNCR26>3.0.CO;2-Z","volume":"88","author":"E Kebebew","year":"2000","unstructured":"Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000;88:1139\u201348.","journal-title":"Cancer"},{"key":"2031_CR3","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/sj.bjc.6600930","volume":"88","author":"G Pellegriti","year":"2003","unstructured":"Pellegriti G, Leboulleux S, Baudin E, Bellon N, Scollo C, Travagli JP, Schlumberger M. Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging. Br J Cancer. 2003;88:1537\u201342.","journal-title":"Br J Cancer"},{"key":"2031_CR4","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1089\/thy.2008.0403","volume":"19","author":"RT Kloos","year":"2009","unstructured":"American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M, Wells Jr SA. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009;19:565\u2013612.","journal-title":"Thyroid"},{"key":"2031_CR5","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/ncpendmet0717","volume":"4","author":"M Schlumberger","year":"2008","unstructured":"Schlumberger M, Carlomagno F, Baudin E, Bidart JM, Santoro M. New therapeutic approaches to treat medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab. 2008;4:22\u201332.","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"2031_CR6","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1053\/j.semnuclmed.2006.03.007","volume":"36","author":"V Rufini","year":"2006","unstructured":"Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumours. Semin Nucl Med. 2006;36:228\u201347.","journal-title":"Semin Nucl Med"},{"key":"2031_CR7","first-page":"67","volume":"33","author":"V Rufini","year":"2008","unstructured":"Rufini V, Treglia G, Perotti G, Leccisotti L, Calcagni ML, Rubello D. Role of PET in medullary thyroid carcinoma. Minerva Endocrinol. 2008;33:67\u201373.","journal-title":"Minerva Endocrinol"},{"key":"2031_CR8","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s002590100614","volume":"28","author":"M Diehl","year":"2001","unstructured":"Diehl M, Risse JH, Brandt-Mainz K, Dietlein M, Bohuslavizki KH, Matheja P, Lange H, Bredow J, K\u00f6rber C, Gr\u00fcnwald F. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. Eur J Nucl Med. 2001;28:1671\u20136.","journal-title":"Eur J Nucl Med"},{"key":"2031_CR9","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1245\/ASO.2004.10.015","volume":"11","author":"JW Groot de","year":"2004","unstructured":"de Groot JW, Links TP, Jager PL, Kahraman T, Plukker JT. Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol. 2004;11:786\u201394.","journal-title":"Ann Surg Oncol"},{"key":"2031_CR10","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s002590000404","volume":"28","author":"S Hoegerle","year":"2001","unstructured":"Hoegerle S, Altehoefer C, Ghanem N, Brink I, Moser E, Nitzsche E. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med. 2001;28:64\u201371.","journal-title":"Eur J Nucl Med"},{"key":"2031_CR11","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1007\/s00259-007-0425-2","volume":"34","author":"B Beuthien-Baumann","year":"2007","unstructured":"Beuthien-Baumann B, Strumpf A, Zessin J, Bredow J, Kotzerke J. Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2007;34:1604\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2031_CR12","doi-asserted-by":"crossref","first-page":"524","DOI":"10.2967\/jnumed.107.047720","volume":"49","author":"KP Koopmans","year":"2008","unstructured":"Koopmans KP, de Groot JW, Plukker JT, de Vries EG, Kema IP, Sluiter WJ, Jager PL, Links TP. 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. J Nucl Med. 2008;49:524\u201331.","journal-title":"J Nucl Med"},{"key":"2031_CR13","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s00330-008-1280-7","volume":"19","author":"M Beheshti","year":"2009","unstructured":"Beheshti M, P\u00f6cher S, Vali R, Waldenberger P, Broinger G, Nader M, Kohlf\u00fcrst S, Pirich C, Dralle H, Langsteger W. The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. Eur Radiol. 2009;19:1425\u201334.","journal-title":"Eur Radiol"},{"key":"2031_CR14","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.ejso.2010.01.001","volume":"36","author":"MC Marzola","year":"2010","unstructured":"Marzola MC, Pelizzo MR, Ferdeghini M, Toniato A, Massaro A, Ambrosini V, Fanti S, Gross MD, Al-Nahhas A, Rubello D. Dual PET\/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: comparison with conventional imaging. Eur J Surg Oncol. 2010;36:414\u201321.","journal-title":"Eur J Surg Oncol"},{"key":"2031_CR15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00259-009-1204-z","volume":"37","author":"BG Conry","year":"2010","unstructured":"Conry BG, Papathanasiou ND, Prakash V, Kayani I, Caplin M, Mahmood S, Bomanji JB. Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET\/CT in the detection of recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2010;37:49\u201357.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2031_CR16","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/00000658-198404000-00014","volume":"199","author":"A Miyauchi","year":"1984","unstructured":"Miyauchi A, Onishi T, Morimoto S, Takai S, Matsuzuka F, Kuma K, Maeda M, Kumahara Y. Relation of doubling time of plasma calcitonin levels to prognosis and recurrence of medullary thyroid carcinoma. Ann Surg. 1984;199:461\u20136.","journal-title":"Ann Surg"},{"key":"2031_CR17","doi-asserted-by":"crossref","first-page":"886","DOI":"10.2967\/jnumed.111.088328","volume":"52","author":"P Castellucci","year":"2011","unstructured":"Castellucci P, Pou Ucha J, Fuccio C, Rubello D, Ambrosini V, Montini GC, Pettinato V, Malizia C, Lodi F, Fanti S. Incidence of increased 68Ga-DOTANOC uptake in the pancreatic head in a large series of extrapancreatic NET patients studied with sequential PET\/CT. J Nucl Med. 2011;52:886\u201390.","journal-title":"J Nucl Med"},{"key":"2031_CR18","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/RLU.0b013e3181d6677c","volume":"35","author":"A Versari","year":"2010","unstructured":"Versari A, Camellini L, Carlinfante G, Frasoldati A, Nicoli F, Grassi E, Gallo C, Giunta FP, Fraternali A, Salvo D, Asti M, Azzolini F, Iori V, Sassatelli R. Ga-68 DOTATOC PET, endoscopic ultrasonography, and multidetector CT in the diagnosis of duodenopancreatic neuroendocrine tumors: a single-centre retrospective study. Clin Nucl Med. 2010;35:321\u20138.","journal-title":"Clin Nucl Med"},{"key":"2031_CR19","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1089\/thy.2009.0342","volume":"20","author":"M Luster","year":"2010","unstructured":"Luster M, Karges W, Zeich K, Pauls S, Verburg FA, Dralle H, Glatting G, Buck AK, Solbach C, Neumaier B, Reske SN, Mottaghy FM. Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography\/computed tomography in the follow-up of medullary thyroid carcinoma. Thyroid. 2010;20:527\u201333.","journal-title":"Thyroid"},{"key":"2031_CR20","first-page":"BP115","volume":"30","author":"E Bombardieri","year":"2003","unstructured":"Bombardieri E, Aktolun C, Baum RP, Bishof-Delaloye A, Buscombe J, Chatal JF, Maffioli L, Moncayo R, Mortelmans L, Reske SN. FDG-PET: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2003;30:BP115\u201324.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2031_CR21","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1677\/ERC-08-0152","volume":"16","author":"A Faggiano","year":"2009","unstructured":"Faggiano A, Grimaldi F, Pezzullo L, Chiofalo MG, Carac\u00f2 C, Mozzillo N, Angeletti G, Santeusanio F, Lombardi G, Colao A, Avenia N, Ferolla P. Secretive and proliferative tumor profile helps to select the best imaging technique to identify postoperative persistent or relapsing medullary thyroid cancer. Endocr Relat Cancer. 2009;16:225\u201331.","journal-title":"Endocr Relat Cancer"},{"key":"2031_CR22","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/00006231-199807000-00005","volume":"19","author":"S Adams","year":"1998","unstructured":"Adams S, Baum RP, Hertel A, Schumm-Dr\u00e4ger PM, Usadel KH, H\u00f6r G. Metabolic (PET) and receptor (SPET) imaging of well- and less well-differentiated tumours: comparison with the expression of the Ki-67 antigen. Nucl Med Commun. 1998;19:641\u20137.","journal-title":"Nucl Med Commun"},{"key":"2031_CR23","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2967\/jnumed.106.036681","volume":"48","author":"SC Ong","year":"2007","unstructured":"Ong SC, Sch\u00f6der H, Patel SG, Tabangay-Lim IM, Doddamane I, G\u00f6nen M, Shaha AR, Tuttle RM, Shah JP, Larson SM. Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med. 2007;48:501\u20137.","journal-title":"J Nucl Med"},{"key":"2031_CR24","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s002590050533","volume":"27","author":"K Brandt-Mainz","year":"2000","unstructured":"Brandt-Mainz K, M\u00fcller SP, G\u00f6rges R, Saller B, Bockisch A. The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer. Eur J Nucl Med. 2000;27:490\u20136.","journal-title":"Eur J Nucl Med"},{"key":"2031_CR25","first-page":"66","volume":"43","author":"S Szak\u00e1ll Jr","year":"2002","unstructured":"Szak\u00e1ll Jr S, Esik O, Bajzik G, Repa I, Dabasi G, Sinkovics I, Agoston P, Tr\u00f3n L. 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med. 2002;43:66\u201371.","journal-title":"J Nucl Med"},{"key":"2031_CR26","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/00006231-200405000-00003","volume":"25","author":"M Gotthardt","year":"2004","unstructured":"Gotthardt M, Battmann A, H\u00f6ffken H, Schurrat T, Pollum H, Beuter D, Gratz S, B\u00e9h\u00e9 M, Bauhofer A, Klose KJ, Behr TM. 18F-FDG PET, somatostatin receptor scintigraphy, and CT in metastatic medullary thyroid carcinoma: a clinical study and an analysis of the literature. Nucl Med Commun. 2004;25:439\u201343.","journal-title":"Nucl Med Commun"},{"key":"2031_CR27","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1177\/107327480501200408","volume":"12","author":"N Khan","year":"2005","unstructured":"Khan N, Oriuchi N, Higuchi T, Endo K. Review of fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in the follow-up of medullary and anaplastic thyroid carcinomas. Cancer Control. 2005;12:254\u201360.","journal-title":"Cancer Control"},{"key":"2031_CR28","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1210\/jc.2007-1211","volume":"92","author":"AL Giraudet","year":"2007","unstructured":"Giraudet AL, Vanel D, Leboulleux S, Aup\u00e9rin A, Dromain C, Chami L, Ny Tovo N, Lumbroso J, Lassau N, Bonniaud G, Hartl D, Travagli JP, Baudin E, Schlumberger M. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab. 2007;92:4185\u201390.","journal-title":"J Clin Endocrinol Metab"},{"key":"2031_CR29","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11307-006-0072-1","volume":"9","author":"A Iagaru","year":"2007","unstructured":"Iagaru A, Masamed R, Singer PA, Conti PS. Detection of occult medullary thyroid cancer recurrence with 2-deoxy-2-[F-18]fluoro-D-glucose-PET and PET\/CT. Mol Imaging Biol. 2007;9:72\u20137.","journal-title":"Mol Imaging Biol"},{"key":"2031_CR30","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.1210\/jc.2007-0938","volume":"92","author":"A Oudoux","year":"2007","unstructured":"Oudoux A, Salaun PY, Bournaud C, Campion L, Ansquer C, Rousseau C, Bardet S, Borson-Chazot F, Vuillez JP, Murat A, Miralli\u00e9 E, Barbet J, Goldenberg DM, Chatal JF, Kraeber-Bod\u00e9r\u00e9 F. Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy. J Clin Endocrinol Metab. 2007;92:4590\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"2031_CR31","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ejso.2007.08.005","volume":"34","author":"D Rubello","year":"2008","unstructured":"Rubello D, Rampin L, Nanni C, Banti E, Ferdeghini M, Fanti S, Al-Nahhas A, Gross MD. The role of 18F-FDG PET\/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: a prospective study. Eur J Surg Oncol. 2008;34:581\u20136.","journal-title":"Eur J Surg Oncol"},{"key":"2031_CR32","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s11307-009-0276-2","volume":"12","author":"TV Bogsrud","year":"2010","unstructured":"Bogsrud TV, Karantanis D, Nathan MA, Mullan BP, Wiseman GA, Kasperbauer JL, Reading CC, Bj\u00f6ro T, Hay ID, Lowe VJ. The prognostic value of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in patients with suspected residual or recurrent medullary thyroid carcinoma. Mol Imaging Biol. 2010;12:547\u201353.","journal-title":"Mol Imaging Biol"},{"key":"2031_CR33","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/MNM.0b013e3283384587","volume":"31","author":"E Skoura","year":"2010","unstructured":"Skoura E, Rondogianni P, Alevizaki M, Tzanela M, Tsagarakis S, Piaditis G, Tolis G, Datseris IE. Role of [(18)F]FDG-PET\/CT in the detection of occult recurrent medullary thyroid cancer. Nucl Med Commun. 2010;31:567\u201375.","journal-title":"Nucl Med Commun"},{"issue":"5 Suppl 13","key":"2031_CR34","first-page":"42","volume":"21","author":"U D\u00f6rr","year":"1994","unstructured":"D\u00f6rr U, Sautter-Bihl ML, Bihl H. The contribution of somatostatin receptor scintigraphy to the diagnosis of recurrent medullary carcinoma of the thyroid. Semin Oncol. 1994;21(5 Suppl 13):42\u20135.","journal-title":"Semin Oncol"},{"key":"2031_CR35","first-page":"912","volume":"37","author":"E Baudin","year":"1996","unstructured":"Baudin E, Lumbroso J, Schlumberger M, Leclere J, Giammarile F, Gardet P, Roche A, Travagli JP, Parmentier C. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. J Nucl Med. 1996;37:912\u20136.","journal-title":"J Nucl Med"},{"key":"2031_CR36","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1046\/j.1365-2265.2001.01175.x","volume":"54","author":"M Papotti","year":"2001","unstructured":"Papotti M, Kumar U, Volante M, Pecchioni C, Patel YC. Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid. Clin Endocrinol. 2001;54:641\u20139.","journal-title":"Clin Endocrinol"},{"key":"2031_CR37","first-page":"567","volume":"64","author":"JC Reubi","year":"1991","unstructured":"Reubi JC, Chayvialle JA, Franc B, Cohen R, Calmettes C, Modigliani E. Somatostatin receptors and somatostatin content in medullary thyroid carcinomas. Lab Invest. 1991;64:567\u201373.","journal-title":"Lab Invest"},{"issue":"12 Suppl","key":"2031_CR38","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12+<2436::AID-CNCR16>3.0.CO;2-D","volume":"80","author":"TM Behr","year":"1997","unstructured":"Behr TM, Gratz S, Markus PM, Dunn RM, H\u00fcfner M, Schauer A, Fischer M, Munz DL, Becker H, Becker W. Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors? Cancer. 1997;80(12 Suppl):2436\u201357.","journal-title":"Cancer"},{"key":"2031_CR39","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s00259-009-1247-1","volume":"37","author":"V Ambrosini","year":"2010","unstructured":"Ambrosini V, Marzola MC, Rubello D, Fanti S. (68)Ga-somatostatin analogues PET and (18)F-DOPA PET in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2010;37:46\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2031_CR40","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1089\/108497804773391694","volume":"19","author":"L Bodei","year":"2004","unstructured":"Bodei L, Handkiewicz-Junak D, Grana C, Mazzetta C, Rocca P, Bartolomei M, Lopera Sierra M, Cremonesi M, Chinol M, M\u00e4cke HR, Paganelli G. Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas. Cancer Biother Radiopharm. 2004;19:65\u201371.","journal-title":"Cancer Biother Radiopharm"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-011-2031-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-011-2031-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-011-2031-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T21:36:14Z","timestamp":1640381774000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-011-2031-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,6]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["2031"],"URL":"https:\/\/doi.org\/10.1007\/s00259-011-2031-6","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,6]]}}}